Evidence map›Paper›PMID 25458952›Full record

ArticleCancer letters2015

MicroRNA-320b promotes colorectal cancer proliferation and invasion by competing with its homologous microRNA-320a.

Jiaojiao Zhou, Mengwen Zhang, Yanqing Huang, Lin Feng, Hailong Chen, Yiwang Hu, Huarong Chen, Kaitai Zhang, Lei Zheng, Shu Zheng

Abstract read
In one paragraph

Article in Cancer letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Neuropilins in the Context of Tumor Vasculature.International journal of molecular sciences · 2019
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. miR-138-5p acts as a tumor suppressor by targeting hTERT in human colorectal cancer.International journal of clinical and experimental pathology · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiaojiao ZhouDepartment of Surgical Oncology, the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, China; The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, 88 Jie-Fang Rd, Hangzhou, Zhejiang 310009, China.
Mengwen ZhangDepartment of Surgical Oncology, the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, China; The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, 88 Jie-Fang Rd, Hangzhou, Zhejiang 310009, China.
Yanqing HuangDepartment of Surgical Oncology, the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, China; The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, 88 Jie-Fang Rd, Hangzhou, Zhejiang 310009, China.
Lin FengState Key Laboratory of Molecular Oncology, Cancer Institute & Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 10021, China; Department of Etiology and Carcinogenesis, Cancer Institute & Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 10021, China; Cancer Institute & Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 10021, China.
Hailong ChenDepartment of Surgical Oncology, the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, China; The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, 88 Jie-Fang Rd, Hangzhou, Zhejiang 310009, China.
Yiwang HuDepartment of Surgical Oncology, the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, China; The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, 88 Jie-Fang Rd, Hangzhou, Zhejiang 310009, China.
Huarong ChenDepartment of Surgical Oncology, the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, China; The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, 88 Jie-Fang Rd, Hangzhou, Zhejiang 310009, China.
Kaitai ZhangState Key Laboratory of Molecular Oncology, Cancer Institute & Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 10021, China; Department of Etiology and Carcinogenesis, Cancer Institute & Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 10021, China; Cancer Institute & Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 10021, China.
Lei ZhengDepartments of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Bunting-Blaustein Building Room 488, Baltimore, MD, USA; Department of Surgery, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Bunting-Blaustein Building Room 488, Baltimore, MD, USA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Bunting-Blaustein Building Room 488, Baltimore, MD, USA. Electronic address: lzheng6@jhmi.edu.
Shu ZhengDepartment of Surgical Oncology, the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, China; The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, 88 Jie-Fang Rd, Hangzhou, Zhejiang 310009, China. Electronic address: zhengshu@zju.edu.cn.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Interrogate the interaction between tumor cells and nerves in the tumor microenvironment of pancreatic cancerR01CA169702 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ZHENG, LEI · 2013 to 2023
$3.6M
Dissecting the mechanisms of immune tolerance within the pancreatic tumor's microK23CA148964 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZHENG, LEI · 2010 to 2014
$888k
NCI NIH HHS K23 CA148964NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA169702
6 · The paper itself

Abstract

Colorectal cancer metastasis is believed to be associated with microRNA dysregulation. However, little is known as to how microRNAs regulate colorectal cancer proliferation, invasion and metastasis. In the present study, we compared the microRNA expression profiles between patients of colorectal cancer at diagnosis with and without liver metastasis. MicroRNA-320b was found to be among those up-regulated in the patient group with metastasis. We subsequently found that microRNA-320b, opposite of its homolog, microRNA-320a that differs by only a single nucleotide, functions in promoting colorectal cancer cell proliferation and invasion. Moreover, we found that overexpression of exogenous microRNA-320b can up-regulate the target genes of microRNA-320a including β-catenin, Neuropilin-1 and Rac-1, which are all known to promote tumor proliferation, invasion and metastasis. These results suggest that microRNA-320b may function in competing with microRNA-320a. Thus, our study has proposed one novel mechanism for controlling colorectal cancer proliferation and invasion through homologous competition between microRNAs. This mechanism may be important for colorectal cancer metastasis.

Indexed as

Cell MovementCell ProliferationApoptosisBiomarkers, TumorBlotting, WesternCell AdhesionColorectal NeoplasmsGene Expression ProfilingHumansLiver NeoplasmsMicroRNAsNeoplasm InvasivenessNeoplasm StagingReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerBiomarkers, TumorMicroRNAsMIRN320 microRNA, humanRNA, MessengerColorectal cancerInvasionMetastasismicroRNA-320amicroRNA-320b

Identifiers

PMID25458952
PMCPMC4397650

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.